Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856Phase 4Completed
- Sponsor
- University of California, San Diego
- Start
- Jan 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of memantine in Alzheimer's disease (AD), sponsored by University of California, San Diego. Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03703856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703856.